Other Events. Establishment of “At the Market” Offering Program On August 21, 2026, Nuvectis Pharma, Inc., a Delaware corporation (the “Company”), entered into an Open Market Sale Agreement SM (the “Sale Agreement”) with Jefferies LLC (“Jefferies”) as sales agent, pursuant to which the Company may offer and sell shares (the “ATM Shares”) of its common stock, $0.00001 par value per share (the “Common Stock”), from time to time through Jefferies. On August 21, 2026, the Company expects to file…

Results of Operations and Financial Condition. On August 4, 2026, Nuvectis Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the second quarter ended June 30, 2026. A copy of such press release is being furnished as Exhibit 99.1 to this report. The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or oth…

Entry into a Material Definitive Agreement. On June 29, 2026, Nuvectis Pharma, Inc. (“Nuvectis” or the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cantor Fitzgerald & Co. (the “Representative”). Pursuant to the Underwriting Agreement, the Company agreed to sell to the Representative, in a firm commitment underwritten public offering (the “Offering”), 5,000,000 shares (the “Firm Shares”) of the Company’s common stock, $0.00001 par value per share (“Com…

Other Events. As previously disclosed, on May 9, 2025, Nuvectis Pharma, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Leerink Partners LLC (the “Agent”) pursuant to which the Company may sell, from time to time, at its option, shares (the “Shares”) of the Company’s common stock (the “Common Stock”), under a prospectus (the “Sales Agreement Prospectus”) through the Agent. On June 29, 2026, the Company determined to lower the amount available for sales under t…

Entry into a Material Definitive Agreement. Haisco License Agreement On June 22, 2026, Nuvectis Pharma, Inc., a Delaware corporation (the “Company”), entered into a license agreement (the “License Agreement”) with Haisco Pharmaceutical Group Co., Ltd. (“Haisco”). Pursuant to the License Agreement, Haisco will grant the Company an exclusive, royalty-bearing license for the development, manufacturing, and commercialization rights of HSK39297 (“NXP100”), a Complement Factor B inhibitor in late-s…

Results of Operations and Financial Condition. On May 5, 2026, Nuvectis Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the first quarter ended March 31, 2026. A copy of such press release is being furnished as Exhibit 99.1 to this report. The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherw…

Results of Operations and Financial Condition. On February 11, 2026, Nuvectis Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the fiscal year ended December 31, 2025. A copy of such press release is being furnished as Exhibit 99.1 to this report. The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or…

Results of Operations and Financial Condition. On November 4, 2025, Nuvectis Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the third quarter ended September 30, 2025. A copy of such press release is being furnished as Exhibit 99.1 to this report. The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended,…

Director — Juan Sanchez, MD: Dr. Juan Sanchez was appointed to the Board of Directors.

Results of Operations and Financial Condition. On August 5, 2025, Nuvectis Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the second quarter ended June 30, 2025. A copy of such press release is being furnished as Exhibit 99.1 to this report. The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or oth…

Other Events. Establishment of “At the Market” Offering Program On May 9, 2025, Nuvectis Pharma, Inc., a Delaware corporation (the “Company”), entered into a Sales Agreement (the “Sales Agreement”) with Leerink Partners LLC (“Leerink Partners”) as sales agent, pursuant to which the Company may offer and sell shares of its common stock, $0.00001 par value per share (the “Common Stock”), from time to time through Leerink Partners. The Company has filed a prospectus supplement (the “Prospectus S…

Results of Operations and Financial Condition. On May 6, 2025, Nuvectis Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the first quarter ended March 31, 2025. A copy of such press release is being furnished as Exhibit 99.1 to this report. The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherw…

Results of Operations and Financial Condition. On February 25, 2025, Nuvectis Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the fiscal year ended December 31, 2024. A copy of such press release is being furnished as Exhibit 99.1 to this report. The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or…

Entry into a Material Definitive Agreement. On February 5, 2025, Nuvectis Pharma, Inc. (“Nuvectis” or the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Lucid Capital Markets, LLC (the “Underwriter”). Pursuant to the Underwriting Agreement, the Company agreed to sell to the Underwriter, in a firm commitment underwritten public offering (the “Offering”), 2,700,000 shares (the “Firm Shares”) of the Company’s common stock, $0.00001 par value per share (“Com…

Results of Operations and Financial Condition. On November 5, 2024, Nuvectis Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the third quarter ended September 30, 2024. A copy of such press release is being furnished as Exhibit 99.1 to this report. The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended,…

Results of Operations and Financial Condition. On August 6, 2024, Nuvectis Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the second quarter ended June 30, 2024. A copy of such press release is being furnished as Exhibit 99.1 to this report. The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or oth…

Results of Operations and Financial Condition. On May 7, 2024, Nuvectis Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the first quarter ended March 31, 2024. A copy of such press release is being furnished as Exhibit 99.1 to this report. The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherw…

Results of Operations and Financial Condition. On March 5, 2024, Nuvectis Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the fiscal year ended December 31, 2023. A copy of such press release is being furnished as Exhibit 99.1 to this report. The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or oth…

Results of Operations and Financial Condition. On November 8, 2023, Nuvectis Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the second quarter ended September 30, 2023. A copy of such press release is being furnished as Exhibit 99.1 to this report. The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended,…

Results of Operations and Financial Condition. On August 9, 2023, Nuvectis Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the second quarter ended June 30, 2023. A copy of such press release is being furnished as Exhibit 99.1 to this report. The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or oth…

Results of Operations and Financial Condition. As of June 30, 2023, Nuvectis Pharma, Inc. (the “ Company ”) has approximately $24.5 million of cash and cash equivalents, an increase of approximately $9.0 million as compared to cash and cash equivalents reported at March 31, 2023. The increase in cash and cash equivalents is primarily attributable to the exercise of previously issued preferred investment options during the second quarter of 2023. The Company estimates that its current cash and…

Results of Operations and Financial Condition. On May 15, 2023, Nuvectis Pharma, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration cleared the Company’s Investigational New Drug Application for NXP900, which incudes the Phase 1 clinical trial protocol. A copy of such press release is being furnished as Exhibit 99.1 to this report.

Results of Operations and Financial Condition. On May 10, 2023, Nuvectis Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the first quarter ended March 31, 2023. A copy of such press release is being furnished as Exhibit 99.1 to this report. The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or other…

Results of Operations and Financial Condition. On March 7, 2023, Nuvectis Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the fiscal year ended December 31, 2022. A copy of such press release is being furnished as Exhibit 99.1 to this report. The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or oth…

Results of Operations and Financial Condition. On November 8, 2022, Nuvectis Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the third quarter ended September 30, 2022. A copy of such press release is being furnished as Exhibit 99.1 to this report. The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended,…